VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
EVLV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
EVLVEvolv Technologies Holdings, Inc.
$4.56$820M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksEVLVBalance Sheet

Evolv Technologies Holdings, Inc. (EVLV) Balance Sheet

7Y historyFree accessUpdated daily

Total debt rose to $41.6M (D/E 0.35) while cash stood at $52.7M, but the current ratio fell to 1.18 from 1.77 in 2024Q1, and deferred revenue declined 19.3% sequentially to $74.5M, signaling a thinning liquidity cushion and potential subscription headwinds.

Income StatementBalance SheetCash FlowRatios

EVLV Balance Sheet

Annual statement

EVLV Balance Sheet

Evolv Technologies Holdings, Inc. (EVLV) balance sheet — 7-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets149.41M151.3M121.45M175.84M292.58M331.12M10.31M20.31M
Cash & Short-Term Investments62.63M69.03M51.94M118.82M230.12M307.7M4.7M17.34M
Cash Only52.7M49.15M37.02M67.16M229.78M307.49M4.7M17.34M
Short-Term Investments9.94M19.89M14.93M51.66M337K206K00
Accounts Receivable39.58M47.06M29.19M26.32M34.77M7.94M1.4M984K
Days Sales Outstanding96.15117.73102.58119.45240.74123.83106.8761.44
Inventory8.66M9.32M16.96M9.51M10.26M2.89M2.74M1.36M
Days Inventory Outstanding37.2548.17138.8974.4872.9554.47286.2893.56
Other Current Assets8.85M25.89M7.51M5.95M4.5M2.29M628K100K
Total Non-Current Assets152.62M153.11M146.61M122.88M55.53M31.74M11.05M4.09M
Property, Plant & Equipment140.39M139.82M137.65M114.12M46.38M23.78M9.32M3.69M
Fixed Asset Turnover1.23x1.04x0.75x0.70x1.14x0.98x0.51x1.59x
Goodwill00000000
Intangible Assets0007M0000
Long-Term Investments381K0376K84K0000
Other Non-Current Assets12.23M13.28M8.58M1.68M9.15M7.95M1.73M407K
Total Assets302.02M304.41M268.06M298.72M348.12M362.86M21.36M24.4M
Asset Turnover0.56x0.48x0.39x0.27x0.15x0.06x0.22x0.24x
Asset Growth %49.54%13.56%-10.26%-14.19%-4.06%1599.17%-12.48%-
Total Current Liabilities126.85M122.98M96.71M82.05M59.13M24.33M12.12M9.33M
Accounts Payable12.25M9.77M10.49M17.4M18.19M6.04M4.44M2.52M
Days Payables Outstanding46.6550.5185.91136.32129.4113.94463.25173.88
Short-Term Debt0011.11M010M2M227K3.42M
Deferred Revenue (Current)302.61M74.92M64.51M47.68M18.27M6.6M3.72M1.55M
Other Current Liabilities016.85M2.72M14M9.14M7.07M1.39M711K
Current Ratio1.18x1.23x1.26x2.14x4.95x13.61x0.85x2.18x
Quick Ratio1.11x1.15x1.08x2.03x4.78x13.49x0.62x2.03x
Cash Conversion Cycle86.75115.38155.5757.61184.2964.36-70.1-18.89
Total Non-Current Liabilities56.32M62.01M53.7M70.35M62M48.25M18.05M73.58M
Long-Term Debt28.74M28.6M0019.68M7.95M16.43M0
Capital Lease Obligations41.67M10.65M12.33M0892K0132K0
Deferred Tax Liabilities00000000
Other Non-Current Liabilities83K6.04M21.11M46.54M23.73M37.83M1M73.27M
Total Liabilities183.16M184.99M150.41M152.4M121.13M72.58M30.16M82.91M
Total Debt41.57M42.24M25.64M1.39M31.69M9.95M16.79M3.65M
Net Debt-11.13M-6.91M-11.37M-65.77M-198.09M-297.55M12.09M-13.7M
Debt / Equity0.35x0.35x0.22x0.01x0.14x0.03x--
Debt / EBITDA-8.42x-------
Net Debt / EBITDA2.25x-------
Interest Coverage-0.44x-18.10x--161.39x-120.90x-0.79x-62.70x-24.49x
Total Equity118.86M119.42M117.65M146.32M226.99M290.27M-8.81M-58.51M
Equity Growth %8.73%1.51%-19.6%-35.54%-21.8%3395.2%84.94%-
Book Value per Share0.660.710.750.981.581.90-0.06-0.41
Total Shareholders' Equity118.86M119.42M117.65M146.32M226.99M290.27M-8.81M-58.51M
Common Stock18K18K16K15K15K14K1K23K
Retained Earnings-402.11M-387.8M-354.66M-298.46M-192.21M-105.8M-93.88M-66.49M
Treasury Stock00000000
Accumulated OCI-113K-141K-32K-53K-10K000
Minority Interest00000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Cash runway and efficacy concerns

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Stabilizes Amid Revenue Growth

Total assets have held near $302-305M over the last three quarters, while equity improved to $118.9M in 2026Q2, suggesting a stabilizing balance sheet despite ongoing losses.

The balance sheet appears to have stabilized after a volatile 2025, with total assets hovering around $302-305M since 2025Q3. Equity has recovered from $92.7M in 2025Q2 to $118.9M in 2026Q2, driven by a reduction in total liabilities from $202.1M to $183.2M. This stabilization, coupled with revenue growth of 34.4% year-over-year, suggests that the company is managing its capital structure while scaling, though the persistent negative retained earnings of -$402.1M indicate that losses continue to erode book value.

Leverage Rises but Remains Manageable

Total debt increased to $41.6M in 2026Q2 from $14.3M a year earlier, lifting D/E to 0.35, yet this remains low relative to peers like OSIS at 0.72.

Evolv's debt has more than doubled over the past year, from $14.3M in 2025Q2 to $41.6M in 2026Q2, while the debt-to-equity ratio rose from 0.15 to 0.35. This increase appears strategic, likely to fund growth initiatives and bridge the gap to profitability, but it also introduces refinancing risk given the company's negative operating margins. However, the absolute debt level is modest relative to total assets of $302M, and the D/E remains below the peer average, suggesting that leverage is not yet a constraint.

Asset Base Shifts Toward Deployed Hardware

PP&E net rose to $140.4M in 2026Q2, representing 46.5% of total assets, while goodwill remains zero, indicating an asset-heavy model with no acquisition-related intangibles.

The asset mix is increasingly dominated by property, plant, and equipment, which grew from $122.2M in 2024Q2 to $140.4M in 2026Q2, now comprising nearly half of total assets. This reflects the company's strategy of deploying hardware as part of its TaaS model, which requires significant upfront investment. The absence of goodwill suggests that growth has been organic, but the high PPE concentration implies that depreciation will continue to weigh on earnings, and the assets may be subject to impairment if technology shifts.

Equity Quality Eroded by Persistent Losses

Retained earnings worsened to -$402.1M in 2026Q2, while equity of $118.9M is supported by paid-in capital, indicating that accumulated losses exceed half of total assets.

The equity base is of low quality, as retained earnings have deteriorated from -$306.6M in 2024Q2 to -$402.1M in 2026Q2, reflecting cumulative losses that outpace any capital raises. The positive equity balance is entirely attributable to contributed capital, which suggests that shareholders' equity is a function of external funding rather than internal profitability. This pattern is typical of growth-stage companies, but it underscores the reliance on future profitability to justify the current capital structure.

Liquidity Buffer Thins Despite Cash Stabilization

Cash rose to $52.7M in 2026Q2, but the current ratio fell to 1.18 from 1.77 in 2024Q1, indicating a shrinking liquidity cushion relative to short-term obligations.

While cash has stabilized around $49-56M over the last three quarters, the current ratio has declined from 1.77 in 2024Q1 to 1.18 in 2026Q2, signaling that current liabilities are growing faster than current assets. This suggests that the company's ability to cover short-term obligations is weakening, and with operating losses persisting, the $52.7M cash balance may only provide a limited runway. Investors should monitor whether the company can achieve cash-flow break-even before needing additional capital.

Deferred Revenue Masks Subscription Health

Deferred revenue fell to $74.5M in 2026Q2 from $92.3M in 2026Q1, a 19.3% sequential decline, which may indicate slowing upfront collections or a shift in contract terms.

The sharp drop in deferred revenue from $92.3M to $74.5M in one quarter is notable, as it could signal that the company is recognizing revenue faster or that new subscription bookings are not generating the same level of upfront cash. This trend warrants investigation, as a sustained decline in deferred revenue might suggest weakening demand or a change in the mix toward hardware sales, which would have implications for future revenue visibility and cash flow stability.

EVLV — Frequently Asked Questions

Quick answers to the most common questions about buying EVLV stock.

What are the total assets of Evolv Technologies Holdings, Inc. (EVLV)?

As of 2025, Evolv Technologies Holdings, Inc. (EVLV) had total assets of $304.4M including $151.3M in current assets.

How much debt does Evolv Technologies Holdings, Inc. (EVLV) have?

Evolv Technologies Holdings, Inc. (EVLV) carries total debt of $42.2M, offset by $69.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Evolv Technologies Holdings, Inc.?

Evolv Technologies Holdings, Inc. (EVLV) has total shareholders' equity (book value) of $119.4M ($0.71 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Evolv Technologies Holdings, Inc.'s current ratio and liquidity?

Evolv Technologies Holdings, Inc. (EVLV) reported a current ratio of 1.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.